The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Aug 31, 2026
Snapshot (as of Aug 31, 2026): Eli Lilly and Company (LLY) pays a $6.69 annual dividend ($1.73 quarterly), yielding 0.57% at $1172.86/share. Next ex-dividend date 2026-08-14. 52+ consecutive years of dividend growth (Dividend King). Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 0.57%
Annual Dividend: $6.69 per share
Payout Ratio: 21.7%
Ex-Dividend Date: 2026-08-14
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 55
Eli Lilly and Company dividend investors are looking at one of the longest-running payers in the pharmaceutical sector, backed by a portfolio anchored in diabetes treatments like Trulicity and Jardiance, oncology drugs like Verzenio, and autoimmune therapies like Taltz. LLY currently pays $6.69 per share annually, with quarterly payments and the next ex-dividend date set for August 14, 2026. The current yield stands at 0.57%, which is low in absolute terms but reflects a stock that has prioritized dividend growth over income delivery. With a beta of 0.506, LLY stock carries below-average price volatility, making it a fit for growth-and-income investors who can accept a modest yield in exchange for a Dividend King's decades of unbroken increases.
Eli Lilly and Company pays out 21.7% of earnings as dividends, a payout ratio classified as conservative (below 40%). That low retention of earnings as dividends leaves substantial room to sustain and grow the payment, supported by a broad commercial portfolio spanning chronic-disease categories like diabetes and oncology where demand is recurring by nature. Eli Lilly and Company dividend safety is further reinforced by the 21.7% payout floor, though pharmaceutical companies face pipeline risk and patent cliffs that can pressure future earnings if key products lose exclusivity.
Eli Lilly and Company dividend history shows a CAGR of 8.3% per year from 2011 to 2025. The per-share payment climbed from $1.96 to $6.00 over that span (2026 data is partial and excluded from the rate calculation). The largest annual increase in the window was 15.4% in 2025, while growth was flat across 2012, 2013, and 2014, when the dividend held at $1.96 per share for three consecutive years.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +15.2% | $3.92 (2022) | $6.00 (2025) |
| 5-Year | +15.2% | $2.96 (2020) | $6.00 (2025) |
| 10-Year | +11.6% | $2.00 (2015) | $6.00 (2025) |
LLY fits growth-and-income investors who want a pharmaceutical company with a long dividend-increase streak and are willing to accept a low current yield in exchange for it. At 0.57%, the yield is classified as low (below 2%), and it sits above the 5-year average yield of 0.39%, meaning the current entry point offers slightly more income than the historical norm. Eli Lilly and Company holds Dividend King status with 52 consecutive years of increases, a streak that spans multiple economic environments and product cycles. What an investor gets here is a disciplined payer growing at 8.3% annually over 14 years. What they give up is meaningful current income.
LLY is a Dividend King — 52 consecutive years of dividend increases.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-14 | $1.7300 |
| 2026-05-15 | $1.7300 |
| 2026-02-13 | $1.7300 |
| 2025-11-14 | $1.5000 |
| 2025-08-15 | $1.5000 |
| 2025-05-16 | $1.5000 |
| 2025-02-14 | $1.5000 |
| 2024-11-15 | $1.3000 |
| 2024-08-15 | $1.3000 |
| 2024-05-15 | $1.3000 |
| Year | Total Dividends |
|---|---|
| 2026 | $5.1900 |
| 2025 | $6.0000 |
| 2024 | $5.2000 |
| 2023 | $4.5200 |
| 2022 | $3.9200 |
Project income from LLY with the LLY dividend calculator or track your full portfolio with the dividend tracker.